

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | | | |
|--|--|--|---|--|---|--|--|
| 1. Name and Address of Reporting Person* <u>COLUMN GROUP L P</u> <hr/> (Last) (First) (Middle) 1700 OWENS STREET SUITE 500 <hr/> (Street) SAN FRANCISCO CA 94158 <hr/> (City) (State) (Zip) | | | 2. Issuer Name and Ticker or Trading Symbol <u>Nurix Therapeutics, Inc. [NRIX]</u> | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) <input type="checkbox"/> Other (specify below) <input type="checkbox"/> | | |
| | | | 3. Date of Earliest Transaction (Month/Day/Year) 07/28/2020 | | | | |
| | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 07/28/2020 | | C | | 600,000 | A | (1) | 683,333 | D ⁽²⁾ | |
| Common Stock | 07/28/2020 | | C | | 875,000 | A | (1) | 1,558,333 | D ⁽²⁾ | |
| Common Stock | 07/28/2020 | | C | | 1,836,000 | A | (1) | 3,394,333 | D ⁽²⁾ | |
| Common Stock | 07/28/2020 | | C | | 1,989,000 | A | (1) | 1,989,000 | D ⁽³⁾ | |
| Common Stock | 07/28/2020 | | C | | 686,274 | A | (1) | 686,274 | D ⁽⁴⁾ | |
| Common Stock | 07/28/2020 | | C | | 686,274 | A | (1) | 686,274 | D ⁽⁵⁾ | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----|--|-----------------|---|----------------------------|--|--|---|--|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Series A-1 Preferred Stock | (1) | 07/28/2020 | | C | | 600,000 | | (1) | (1) | Common Stock | 600,000 | \$0.00 | 0 | D ⁽²⁾ | |
| Series A-2 Preferred Stock | (1) | 07/28/2020 | | C | | 875,000 | | (1) | (1) | Common Stock | 875,000 | \$0.00 | 0 | D ⁽²⁾ | |
| Series B Preferred Stock | (1) | 07/28/2020 | | C | | 1,836,000 | | (1) | (1) | Common Stock | 1,836,000 | \$0.00 | 0 | D ⁽²⁾ | |
| Series B Preferred Stock | (1) | 07/28/2020 | | C | | 1,989,000 | | (1) | (1) | Common Stock | 1,989,000 | \$0.00 | 0 | D ⁽³⁾ | |
| Series D Preferred Stock | (1) | 07/28/2020 | | C | | 686,274 | | (1) | (1) | Common Stock | 686,274 | \$0.00 | 0 | D ⁽⁴⁾ | |
| Series D Preferred Stock | (1) | 07/28/2020 | | C | | 686,274 | | (1) | (1) | Common Stock | 686,274 | \$0.00 | 0 | D ⁽⁵⁾ | |

1. Name and Address of Reporting Person*
COLUMN GROUP L P

 (Last) (First) (Middle)
 1700 OWENS STREET
 SUITE 500

 (Street)
 SAN FRANCISCO CA 94158

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Svennilson Peter

| | | |
|-------------------|---------|----------|
| (Last) | (First) | (Middle) |
| 1700 OWENS STREET | | |
| SUITE 500 | | |
| <hr/> | | |
| (Street) | | |
| SAN FRANCISCO | CA | 94158 |
| <hr/> | | |
| (City) | (State) | (Zip) |

Explanation of Responses:

1. The Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.
2. The securities are directly held by The Column Group, LP ("TCG LP"), and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svenilsson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
3. The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svenilsson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
4. The securities are directly held by Ponoii Capital, LP ("Ponoii LP"), and indirectly held by Ponoii Management, LLC ("Ponoii LLC"), the general partner of Ponoii LP. The managing partners of Ponoii LLC are David Goeddel, Peter Svenilsson and Tim Kutzkey. The managing partners of Ponoii LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
5. The securities are directly held by Ponoii Capital II, LP ("Ponoii II LP"), and indirectly held by Ponoii II Management, LLC ("Ponoii II LLC"), the general partner of Ponoii II LP. The managing partners of Ponoii II LLC are David Goeddel, Peter Svenilsson and Tim Kutzkey. The managing partners of Ponoii II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

Remarks:

Due to SEC restrictions on the number of reporting owners, this is Form 2 of 2.

/s/ Jennifer J. Carlson, Attorney-in-Fact 07/29/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.